Local Infiltration of Tranexamic Acid in Breast Reduction for Symptomatic Macromastia.
Abstract
[BACKGROUND] With a surge of tranexamic acid (TXA) use in the plastic surgery community and a constant demand for breast reduction for symptomatic macromastia, questions about the benefits and risks emerge. The aims of this study are to evaluate and compare outcomes of patients undergoing breast reduction while receiving local TXA as opposed to standard procedure without TXA and to assess intraoperative bleeding and operative time.
[METHODS] A retrospective review of breast reductions at a single institution from June 2020 to December 2021 was performed. The breast was infiltrated with tumescent solution at the time of surgery, with or without TXA. The population was divided into 2 groups: the TXA receiving group and tumescent only group. Demographics, intraoperative bleeding, operative time, complications, and drain duration were compared between groups. T test and χ 2 test analyses were performed on IBM SPSS.TM.
[RESULTS] A total of 81 patients and 162 breasts were included. Mean age among patients was 30 ± 13.44 years. Mean SN-N distance was 32.80 ± 3.62 cm. Average resected breast specimen weight was 903.21 ± 336.50 g. Mean operating room time was 159 minutes. Intraoperative blood loss and operative time were not statistically different between groups ( P = 0.583 and P = 0.549, respectively). T-junction dehiscence was lower in the TXA group ( P = 0.016). Incidence of suture granulomas was lower in the TXA group ( P = 0.05). Drain duration was statistically significantly higher in the TXA group ( P = 0.033).
[CONCLUSIONS] No decreases in intraoperative blood loss, operative time, or hematoma were seen after local administration of TXA during breast reduction. The rate of overall complications was not increased by using TXA, and incidence of T-junction dehiscence was lower in the TXA group lending to TXA's relatively safe profile. More research is necessary to further elucidate the TXA-related benefits in standard breast reductions.
[METHODS] A retrospective review of breast reductions at a single institution from June 2020 to December 2021 was performed. The breast was infiltrated with tumescent solution at the time of surgery, with or without TXA. The population was divided into 2 groups: the TXA receiving group and tumescent only group. Demographics, intraoperative bleeding, operative time, complications, and drain duration were compared between groups. T test and χ 2 test analyses were performed on IBM SPSS.TM.
[RESULTS] A total of 81 patients and 162 breasts were included. Mean age among patients was 30 ± 13.44 years. Mean SN-N distance was 32.80 ± 3.62 cm. Average resected breast specimen weight was 903.21 ± 336.50 g. Mean operating room time was 159 minutes. Intraoperative blood loss and operative time were not statistically different between groups ( P = 0.583 and P = 0.549, respectively). T-junction dehiscence was lower in the TXA group ( P = 0.016). Incidence of suture granulomas was lower in the TXA group ( P = 0.05). Drain duration was statistically significantly higher in the TXA group ( P = 0.033).
[CONCLUSIONS] No decreases in intraoperative blood loss, operative time, or hematoma were seen after local administration of TXA during breast reduction. The rate of overall complications was not increased by using TXA, and incidence of T-junction dehiscence was lower in the TXA group lending to TXA's relatively safe profile. More research is necessary to further elucidate the TXA-related benefits in standard breast reductions.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 약물 | txa
|
트라넥삼산 | dict | 13 | |
| 해부 | breast
|
유방 | dict | 8 | |
| 시술 | breast reduction
|
유방성형술 | dict | 4 | |
| 합병증 | dehiscence
|
상처열개 | dict | 2 | |
| 약물 | tranexamic acid
|
트라넥삼산 | dict | 2 | |
| 해부 | breasts
|
scispacy | 1 | ||
| 해부 | blood
|
scispacy | 1 | ||
| 합병증 | hematoma
|
혈종 | dict | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | macromastia
|
C0020565
Hypertrophy of Breast
|
scispacy | 1 | |
| 질환 | bleeding
|
C0019080
Hemorrhage
|
scispacy | 1 | |
| 질환 | breast reductions
|
C0191922
Reduction mammaplasty
|
scispacy | 1 | |
| 질환 | intraoperative bleeding
|
scispacy | 1 | ||
| 질환 | blood loss
|
C0019080
Hemorrhage
|
scispacy | 1 | |
| 질환 | granulomas
|
C0018188
Granuloma
|
scispacy | 1 | |
| 질환 | breast specimen
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | χ 2
|
scispacy | 1 |
MeSH Terms
Adult; Young Adult; Hypertrophy; Antifibrinolytic Agents; Mammaplasty; Tranexamic Acid; Breast; Adolescent; Humans; Blood Loss, Surgical
📑 인용 관계
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.